Optimal Nozzle Position and Patient’s Posture to Enhance Drug Delivery into the Peritoneum during Rotational Intraperitoneal Pressurized Aerosol Chemotherapy in a Swine Model
暂无分享,去创建一个
J. Park | S. Park | G. Yim | S. Shim | HeeSeung Kim | J. Chung | Eun Ji Lee | Seungmee Lee | Suk-Joon Chang | San-Hui Lee | S. Lee | D. Hwang | Dayoung Kim | K. Pak | S. Oh | Eun Joo Lee | on behalf of the KoRIA Trial Group
[1] J. Park,et al. Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model , 2022, Journal of gynecologic oncology.
[2] J. C. Lee,et al. Ideal Nozzle Position During Pressurized Intraperitoneal Aerosol Chemotherapy in an Ex Vivo Model , 2021, AntiCancer Research.
[3] M. Pocard,et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.
[4] J. C. Lee,et al. Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum , 2021, Drug delivery.
[5] S. Park,et al. Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review. , 2020, Gland surgery.
[6] S. Park,et al. Rotational intraperitoneal pressurized aerosol chemotherapy in a porcine model. , 2020, Gland surgery.
[7] J. C. Lee,et al. Evaluation of a Novel Prototype for Pressurized Intraperitoneal Aerosol Chemotherapy , 2020, Cancers.
[8] G. Song,et al. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy , 2019, Medicine.
[9] M. Hübner,et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. , 2019, The Lancet. Oncology.
[10] W. Solass,et al. Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study , 2018, Gastroenterology research and practice.
[11] Ryan J. Hendrix,et al. Palliative Management of Advanced Peritoneal Carcinomatosis. , 2018, Surgical oncology clinics of North America.
[12] N. Aaronson,et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer , 2018, The New England journal of medicine.
[13] E. Förster,et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model , 2016, Journal of Cancer Research and Clinical Oncology.
[14] E. Förster,et al. Evaluating the Effect of Micropump© Position, Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. , 2016, Anticancer research.
[15] E. Förster,et al. Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) , 2016, Annals of Surgical Oncology.
[16] W. Solass,et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] L. Lambert. Looking up: Recent advances in understanding and treating peritoneal carcinomatosis , 2015, CA: a cancer journal for clinicians.
[18] P. Dankers,et al. Targeting the peritoneum with novel drug delivery systems in peritoneal carcinomatosis: a review of the literature. , 2015, Anticancer research.
[19] N. Gourtsoyiannis,et al. Peritoneal carcinomatosis , 2014, European Radiology.
[20] S. Loibl,et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.